Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

doi:10.1186/1471-2334-8-136

BMC Infectious Diseases
Volume 8

Viewing options:

Abstract
Full text
PDF (273KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Manosuthi W
Tantanathip P
Prasithisirikul W
Likanonsakul S
Sungkanuparph S

on PubMed

Manosuthi W
Tantanathip P
Prasithisirikul W
Likanonsakul S
Sungkanuparph S
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

Weerawat Manosuthi¹^,2 , Preecha Tantanathip¹ , Wisit Prasithisirikul¹ , Sirirat Likanonsakul¹ and Somnuek Sungkanuparph²

¹Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand

²Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand

author email corresponding author email

BMC Infectious Diseases 2008, 8:136doi:10.1186/1471-2334-8-136


Published:	14 October 2008

Abstract

Background

To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.

Methods

A prospective cohort study was conducted among 140 antiretroviral-naïve patients who were enrolled to initiate d4T, 3TC and NVP between November 2004 and March 2005. The objectives were to determine immunological and virological responses after 144 weeks of antiretroviral therapy. Seventy patients with tuberculosis also received rifampicin during the early period of antiviral treatment (TB group).

Results

Of all, median (IQR) baseline CD4 cell count was 31 (14–79) cells/mm³; median (IQR) baseline HIV-1 RNA was 433,500 (169,000–750,000) copies/mL. The average body weight was 55 kilograms. By intention-to-treat analysis at 144 weeks, the overall percentage of patients who achieved plasma HIV-1 RNA <50 copies/mL was 59.3% (83/140). In subgroup analysis, 61.4% (43/70) patients in TB group and 57.1% (40/70) patients in control group achieved plasma HIV-1 RNA <50 copies/mL (RR = 1.194, 95%CI = 0.608–2.346, P = 0.731). Eight (5.8%) patients discontinued d4T due to neuropathy and/or symptomatic lactic acidosis.

Conclusion

The overall durability and efficacy of antiviral response of d4T, 3TC and NVP are satisfied and they are not different between HIV-1 infected patients with and without co-administration of rifampicin due to tuberculosis. However, stavudine-related adverse effects are concerns.

Trial registration

ClinicalTrials.gov Identifier NCT00703898